AstraZeneca's COPD Drug Succeeds in Late-Stage Trials, Boosting Blockbuster Hopes
Summary
AstraZeneca's COPD treatment showed positive results in two late-stage clinical trials, supporting peak annual sales projections exceeding $5 billion.
Prepared by the newsroom with AI assistance; the original link is always provided
Pharmaceutical giant AstraZeneca has achieved positive results in two late-stage clinical trials for its new chronic obstructive pulmonary disease (COPD) medication.
The comprehensive trial data reinforces expectations that the treatment could become a major breakthrough in managing COPD. The success also strengthens the company's projections that peak annual sales for the drug could surpass $5 billion.
The positive late-stage outcomes bolster AstraZeneca's commercial outlook and solidify its presence in the respiratory therapeutics market.
Source: CNBC
Read the original →Latest news
Bank CenterCredit Repurchases Shares for 18.2B Tenge on KASE
Bank CenterCredit JSC has repurchased 4.1 million of its common shares on the Kazakhstan Stock Exchange for 18.2 billion tenge.
Source: KASE
Home Credit Bank Bonds Added to KASE T+ List
Starting October 8, Home Credit Bank bonds (KZQ000001213, HCBNe1) will be included in the KASE T+ List.
Source: KASE
KASE Publishes Member Activity Rankings for September 2026
Kazakhstan Stock Exchange has released its exchange member activity rankings for September 2026 on its official website.
Source: KASE
KASE Index rises 0.25% to 7,862.81 points
On October 7, the KASE Index climbed by 0.25% to settle at 7,862.81 points.
Source: KASE